KPTI Stock Down on Mixed Phase III Myelofibrosis Combo Study Data

Karyopharm shares plunged 18% after mixed Phase III data for the selinexor combination in myelofibrosis showed a spleen benefit but no symptom improvement, raising efficacy and approval concerns. The results increase regulatory and commercial risk for the program and are likely to pressure near-term valuation and investor confidence until a full data readout and regulator/management commentary are available.

Analysis

Karyopharm shares plunged 18% after mixed Phase III data for the selinexor combination in myelofibrosis showed a spleen benefit but no symptom improvement, raising efficacy and approval concerns. The results increase regulatory and commercial risk for the program and are likely to pressure near-term valuation and investor confidence until a full data readout and regulator/management commentary are available.